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to be innocent and of no clinical significance. 
However, they also add that the ratio may help 
diagnose MM in patients with CKD or protein-
uria (or both). They diagnosed 5 patients with 
MM (5.4%) and no cases with other MGs. In 5 
patients with MM, the ratio exceeded 100 in 4 
cases, and in 1 case, the ratio was 0.02.4 In an-
other study, the kappa/lambda ratio was abnor-
mal in more than 90% of patients with MM, and 
in most cases, an involved:uninvolved FLC ratio 
was highly increased (>100).5 In other MGs, espe-
cially monoclonal gammopathy of undetermined 
significance and AL, the kappa/lambda ratio is 
often lower than 100.2 In 87 patients with CKD 
or proteinuria (or both), after the exclusion of 
MM patients, a median kappa/lambda ratio was 
1.92 and it was abnormal in 39% of the patients. 
The authors did not provide data on the median 
kappa/lambda ratio in a group of non-MM pa-
tients with an abnormal ratio. The median value 
in the whole group (1.92) was much lower than 
100, but we do not know whether there were pa-
tients with a ratio  exceeding 50 or 100 (<0.02 or 
0.01 in the case of the lambda chain, respective-
ly). The tables included in the paper provide no 
information on the ranges of the kappa/lambda 
ratio. Probably these 39% of non-MM patients 
were characterized with an abnormal but rela-
tively low ratio. We agree with the authors that 
any abnormal ratio value (eg, <100) does not ex-
clude the presence of MM.3
The International Myeloma Working Group 
(IMWG) recommends the serum FLC assay in 
combination with serum protein electrophore-
sis (SPEP) and serum immunofixation to screen 
for MG other than AL, which requires all the se-
rum tests as well as 24-hour urine immunofixa-
tion.2 Immunofixation together with the serum 
FLC assay has a sensitivity of 93.8% and a speci-
ficity of 96.8% in patients examined for an MG.6 
The FLC analysis performed along with SPEP and 
immunofixation may reduce the need for urine 
The serum free light chain (FLC) assay (Freelite) 
is an antibody-based system that measures kap-
pa and lambda immunoglobulin light chains that 
are unbound to heavy chains in serum. Freelite is 
a very sensitive method that allows to detect low 
concentrations of monoclonal FLCs. The measure-
ment of serum FLC is useful in diagnosis, moni-
toring, prognosis, and assessing risk of progres-
sion of monoclonal gammopathies (MGs) where 
plasma cell clone produces only one type of FLC 
or intact immunoglobulin with a related over-
production of FLC.1,2 In this assay, the reference 
range for the free kappa/lambda light chain ra-
tio is 0.26 to 1.65.3
The paper by Niewmierzycka et al.4 published 
in the current issue of the Polish Archives of In-
ternal Medicine, focuses on the use of the FLC as-
say to identify MG in patients with chronic kid-
ney disease (CKD) or proteinuria (or both). The 
presence of monoclonal protein in patients with 
these kidney disorders may have varied etiolo-
gy including multiple myeloma (MM), immuno-
globulin light chain amyloidosis (AL), light chain 
deposition disease, MGs related to other diseas-
es (eg, systemic lupus erythematosus), and MG 
of an unknown origin (in patients with a kidney 
disorder not related to MG, eg, diabetes). The pa-
per by Niewmierzycka et al.4 is the first to address 
the prevalence of an abnormal kappa/lambda ra-
tio in an unselected group of patients with pro-
teinuria or CKD of an unknown origin (or both). 
Patients with these kidney disorders are very of-
ten referred for diagnostic workup for MG, and 
the FLC assay has become a standard diagnostic 
method in this clinical scenario.
Niewmierzycka et al.4 reported that the per-
centage of an abnormal rFLC was highly prev-
alent (42.5%) regardless of the proteinuria lev-
el, estimated glomerular filtration rate (eGFR), 
or histopathological diagnosis on kidney bi-
opsy. The authors conclude that an abnormal 
kappa/lambda ratio, although common, appears 
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origin (defined by authors as a reduced eGFR of 
less than 60 ml/min/1.73 m2 without protein-
uria), 64% of the patients with proteinuria also 
had an eGFR of less than 60 ml/min/1.73 m2. The 
authors could have reported the kappa/lambda 
ratio in patients with proteinuria and reduced 
eGFR and those with proteinuria and an eGFR 
of less than 60 ml/min/1.73 m2.
Patients with either polyclonal hypergamma-
globulinemia (in infectious or inflammatory dis-
orders) or renal impairment often have elevated 
kappa and lambda chains (even 30- to 40-fold); 
however, the kappa/lambda ratio usually remains 
normal or slightly increased.2,3,5,6,11,12 As explained 
by the authors, a slightly increased ratio in renal 
insufficiency is caused by reduced physiological 
clearance and, therefore, a shorter physiological 
half-life of kappa chains.1,13 These cases require 
careful interpretation and highlight the impor-
tance of considering additional clinical and lab-
oratory parameters when interpreting FLC assay 
results. A study evaluating the kappa/lambda ra-
tio in patients with dialysis-dependent renal fail-
ure found that the ratio may increase to 3.1, sug-
gesting that the modified ratio (with higher val-
ues) should be used for detecting MG (0.37–3.1 
vs 0.26–1.65) in this group of patients.11 Anoth-
er study confirmed that a slightly increased ra-
tio up to 3.1 was observed with increased serum 
creatinine levels; therefore, renal reference inter-
vals are recommended.8 A ratio exceeding 3.1 is 
unlikely to be caused by renal insufficiency alone. 
In the case of a ratio between 1.65 and 3.1 in the 
context of renal insufficiency, further investiga-
tion with a 24-hour urine protein electrophore-
sis and urine immunofixation would help guide 
the interpretation of the results.
Niewmierzycka et al.4 could have reported 
the percentage of patients with an abnormal 
ratio according to the renal reference range in 
the group of patients with an eGFR of less than 
60 ml/min/1.73 m2 (72% of the patients includ-
ed into the study) because the median values of 
the kappa/lambda ratio in patients with CKD and 
in patients with CKD and proteinuria were with-
in the renal reference range (3.07 vs 3.1 and 1.92 
vs 3.1, respectively).
Another cause of an abnormal ratio in pa-
tients without MG is polyclonal hypergamma-
globulinemia, caused by an increased synthesis 
of immunoglobulins and FLCs.11 If the authors 
had performed SPEP in every patient, we would 
have known how many of them had polyclonal 
hypergammaglobulinemia, for instance, in the 
course of glomerular disease.
Despite the above limitations, the study by 
Niewmierzycka et al.4 clearly shows that the prev-
alence of an abnormal, especially borderline, rFLC 
among patients with proteinuria or CKD of un-
known origin (or both) is very high and its in-
terpretation requires the inclusion of eGFR and 
further tests (SPEP, immunofixation) within the 
clinical context.
protein studies in the initial diagnostic workup 
for most MGs.7 The study by Niewmierzycka et 
al.4 would provide more valuable information if 
SPEP and immunofixation had been performed 
together with the FLC assay. These methods are 
less sensitive but more specific for MM and MG. 
If serum kappa and lambda light chains and the 
kappa/lambda ratio are within the reference rang-
es, and the results of SPEP and immunofixation 
are normal, it is unlikely that the patient has an 
MG.5,8 Conversely, an abnormal ratio, along with 
an increase in either kappa or lambda chain, sup-
ports the diagnosis of an MG and requires fur-
ther diagnostic workup.
In 2014, the IMWG updated the criteria for the 
diagnosis of MM and other MGs.9 A diagnosis of 
symptomatic MM requires the presence of clon-
al bone marrow (BM) plasma cells (PC) ≥10% or 
biopsy-proven bony or extramedullary plasma-
cytoma, and any of the myeloma-defining events 
(evidence of end-organ damage that may be at-
tributed to the underlying PC proliferative dis-
order [CRAB: hypercalcemia, renal insufficien-
cy, anemia, bone lesions], clonal BM PC ≥60%, 
involved:uninvolved serum FLC ratio ≥100 with 
involved FLC ≥100 mg/l, and >1 focal lesions on 
magnetic resonance imaging). In a previous def-
inition of MM,10 one of the required criteria was 
the presence of serum or urinary monoclonal pro-
tein (or both) detected by the FLC assay and im-
munofixation without a determined kappa/lamb-
da ratio. In that case, the authors’ claim that the 
IMWG does not provide any particular cut-off 
value for the kappa/lambda ratio that could be 
considered more specific or sensitive to diagnose 
MM is not justified. The authors do not specify 
when the data were collected.
We agree with the authors that an abnormal 
kappa/lambda ratio alone in patients with pro-
teinuria or CKD (or both) is not enough to diag-
nose MM. However, along with other tests, it is 
essential to diagnose MM and other MGs.
A high prevalence of patients with an abnormal 
kappa/lambda ratio in this study was explained by 
a reduced eGFR and systemic stimulation of the 
immune system in the course of glomerular dis-
ease. The first cause is probably more important 
because the median kappa/lambda ratio in pa-
tients with CKD was higher than that in patients 
with both nephrotic and nonnephrotic protein-
uria (3.07 vs 1.64 and 3.07 vs 1.48, respectively), 
and the percentage of patients with an abnormal 
rFLC in patients with CKD was higher than that 
in patients with proteinuria (47.6% vs 34.8%).4 
The ratio tended to increase together with an in-
creasing CKD stage. The effect of the proteinuria 
level (glomerular disease) may also be shown by 
a higher median kappa/lambda ratio in patients 
with nephrotic syndrome than those with non-
nephrotic proteinuria (1.64 vs 1.48). The abnor-
mal ratio in patients with proteinuria may also 
be explained by a reduced eGFR. Tables 3a and 3b 
in the paper by Niewmierzycka et al.4 show that 
apart from patients with CKD of an unknown 
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